FlandersBio on Twitter

Follow us on Twitter

Archive for May 2016 - News

Archive for May 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Sir Gregory Winter joins Biosceptre Board


Biosceptre announces today that Sir Gregory Winter, founder of Cambridge Antibody Technology, Domantis and a co-founder of Bicycle Therapeutics Limited has joined the Board as a non-executive Director. read more

Syncona Company Blue Earth Diagnostics Receives US Approval for Novel Prostate Cancer Diagnostic Tool


Syncona LLP (“Syncona”), the evergreen healthcare investment company founded by the Wellcome Trust, announces today that its majority owned subsidiary, Blue Earth Diagnostics Ltd. (“BED”), a private diagnostics company, has received approval by the U.S. Food and Drug Administration (FDA) for a unique molecular imaging agent called Axumin™ (fluciclovine F 18) that identifies prostate cancer recurrence. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. read more

Diagnostica in België: R&D is top, maar commercialisatie kan beter


De eerste BioVox White Paper kijkt kritisch naar de uitdagingen en de opportuniteiten in de diagnosticasector. BioVox publiceert vandaag samen met Belgische experten uit de diagnosticawereld een rapport dat een kritisch inzicht geeft in de opportuniteiten en uitdagingen van een sector met duidelijk potentieel: het opsporen van ziektes staat sinds kort ook op de radar van Google en andere ICT-bedrijven. Binnen de gezondheidssector zelf, blijven de diagnosticabedrijven voorlopig ondergewaardeerd: diagnostica beïnvloeden meer dan 70% van de beslissingen, maar zien slechts 2% van het totale gezondheidsbudget hun richting uitkomen. Ook VC's houden hun portefeuille liever gesloten. read more

Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial


Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the completion of the 21-day safety follow-up of the last patient enrolled in the third dose level cohort in its Phase I/IIa clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells with NKG2D receptor in Acute Myeloid Leukemia and Multiple Myeloma patients. No safety issues were reported. read more



Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that a post-hoc analysis of the worldwide Phase II TITAN study of its wholly-owned Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (aTTP), will be presented at the 21st Congress of the European Hematology Association (EHA), being held from 9-12 June 2016 in Copenhagen, Denmark. read more

FITZROY Phase 2 study with filgotinib in Crohn's Disease presented as late breaker at DDW 2016


25 May 2016, 22.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW[1]) 2016 in San Diego, CA, USA, held from 21-24 May. read more

Multiplicom receives €1.9M grant to develop innovative liquid biopsy based cancer tests


Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients. read more

Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)


Galapagos NV (Euronext & NASDAQ: GLPG) reports the successful completion of the discussions with the regulatory authorities in the US and Europe and discloses the doses for the FINCH global Phase 3 program with filgotinib in RA. The FINCH program will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily, globally addressing a broad RA patient population, with dosing expected to begin in Q3'16. The FINCH Phase 3 program will also contain a dedicated male patient testicular safety study. read more

ONTOFORCE and Tenacs Healthcare present groundbreaking healthcare search platform


The Belgian companies ONTOFORCE and Tenacs Healthcare have teamed up to create InsightHealthcare – an innovatory platform which enables users to consult healthcare data in a new and efficient way. ONTOFORCE opened up its DISQOVER platform to Tenacs Healthcare, that was looking for the best way to share their wide range of data. read more

Record number of participants for the 12th edition of Europe’s leading life sciences conference Knowledge for Growth next Thursday May 26th in Ghent, Belgium: Novel Solutions for Health and Food


FlandersBio’s annual life sciences conference Knowledge for Growth is taking place for the 12th time in Ghent (Belgium) this year. A record number of 1,200 life science professionals from 470 companies & 16 different countries have registered, making Knowledge for Growth more and more a global impact conference. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top